|
Sean McNicholas is senior vice president, Strategic Partnerships and Global Market Access, for the Global Pharmaceutical Business of Schering-Plough Corporation.
McNicholas is responsible for the cholesterol-management therapy ZETIA and the ezetimibe/ simvastatin combination product VYTORIN, both of which are part of a joint venture with Merck & Co., Inc. He also has responsibility for overseeing Schering-Plough's U.S. managed care efforts. McNicholas and his team are working through the Merck/Schering-Plough Pharmaceuticals joint venture to achieve a number of objectives, including charting the future for ZETIA in Japan.
McNicholas joined Schering-Plough in 2002 as vice president, Marketing, with responsibility for Schering-Plough's allergy franchise, respiratory and dermatological products. He came to Schering-Plough from SYN.X, Pharma Inc., in Toronto, Canada, where he served as president and CEO. Previously, he held various sales, marketing and strategic planning positions with Eli Lilly and Pharmacia Corporation.
McNicholas holds a B.S. degree in environmental biology from Swansea University, Wales, Great Britain, and an M.S. degree in plant physiology from the University of Alberta, Canada. | 